MedPath

A clinical trial for 8 continuous weeks intake of HK1502 that are solid preparations blended with vitamin.

Not Applicable
Conditions
ot applicable
Registration Number
JPRN-UMIN000033381
Lead Sponsor
Kojinkai, Association of Medical Corporation Hosui General Medical Clinic.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
23
Inclusion Criteria

Not provided

Exclusion Criteria

1)Subjects who suffer any disease at present and who are going to take continuous medical treatments during the clinical trial, or who are going to use the over-the-counter drug. 2)Subjects who have trauma on the middle fingertip of the left hand, and who have a negative influence on the skin AGE fluorometry. 3)Subjects who have hypersensitivity or allergic reaction to a certain drug medicine or food. 4)Subjects who have an operation career such as hepatectomy, gastrectomy, gastrointestinal suturesin, intestinal resection, transplanting and others in a digestive organ. 5)Subjects who have impaired respiratory and cardiovascular organ. 6)Subjects with experience of alcoholism, or who drink liquor excessively(pure alcohol conversion : over-60g per day). 7)Subjects who have participated in other clinical trials and use tests that apply foods and others within the last 12 weeks prior to the current clinical trial. 8)Subjects who apply to the following. (1)Male subjects who donated 400ml of blood within the last 12 weeks prior to the current clinical trial. In female, within the last 16 weeks. (2)Subjects who donated 200ml of blood within the last 4 weeks prior to the current clinical trial. (3)Subjects who donated components of blood such as blood platelet and blood plasma within the last 2 weeks prior to the current clinical trial. (4)Subjects who have had experiences of a blood collecting conforming to the above matters. 9)Subjects who are the pregnant or breast-feeding woman. 10)Subjects who are planning to become the pregnant woman during the clinical trial. 11)Others who have been determined ineligible or undesirable by investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
*Skin AGE fluorometry *Doctor's findings such as subjective or objective symptoms and medical observations after the clinical trial start
Secondary Outcome Measures
NameTimeMethod
*Questionnaire survey(five-point scale) *Physical examinations such as height, body weight, blood pressure and others *Subject diary(doctor's findings such as expression presence or absence of adverse events)
© Copyright 2025. All Rights Reserved by MedPath